Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Semaglutide for Weight Loss and Metabolic Parameters in Spinal Cord Injury
NCT03292315Phase 4Completed
- Sponsor
- James J. Peters Veterans Affairs Medical Center
- Start
- Oct 2018
- Primary completion
- Mar 2020
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of semaglutide in obesity and prediabetes (2 arms), sponsored by James J. Peters Veterans Affairs Medical Center. Primary endpoints: Body Weight at Week 26, Homeostatic Model Assessment of Insulin Resistance at Week 26 and 1 more. Started Oct 2018; status: completed.
02
Drugs
03
Conditions
obesityprediabetes
Beyond the preview
Go deeper on NCT03292315.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03292315.